The number needed to vaccinate (NNV) and population extensions of the NNV: comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over

被引:52
作者
Kelly, H
Attia, J
Andrews, R
Heller, RF
机构
[1] Victorian Infect Dis Reference Lab, Div Epidemiol, Melbourne, Vic 3053, Australia
[2] Univ Newcastle, Ctr Clin Epidemiol & Biostat, Newcastle, NSW, Australia
[3] Univ Melbourne, Dept Paediat, Murdoch Childrens Res Inst, Int Child Hlth,Clin Epidemiol & Biostat Unit, Melbourne, Vic, Australia
[4] Univ Manchester, Evidence Populat Hlth Unit, Manchester, Lancs, England
关键词
number needed to vaccinate; influenza vaccine; pneumococcal vaccine;
D O I
10.1016/j.vaccine.2003.11.052
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The number needed to treat (NNT) and population extensions of the NNT describe the population outcomes of disease treatment, usually for chronic diseases. We have developed similar measures for vaccine preventable diseases based on the number needed to vaccinate. These measures quantify the number of people, or the number of vaccine doses, needed to prevent one event due to disease per year and allow the calculation of the vaccine cost to prevent one event due to disease per year. We used this method to compare influenza and pneumococcal vaccine programmes for people aged 65 years or more. We calculated the vaccine cost ($AUD) to prevent a case of disease, a hospitalisation or a death due to influenza or invasive pneumococcal disease each year in this age group. For influenza, the vaccine costs were $598 to prevent one case per year, $10,787 per hospitalisation prevented and $74,801 per death prevented each year. We assumed all cases of invasive pneumococcal disease were hospitalised so the vaccine cost of $11,494 per case prevented was the same as the vaccine cost per hospitalisation prevented, while the vaccine cost per death prevented each year was $49,972. These results suggest the vaccine costs for the prevention of one hospitalisation or one death each year due to invasive pneumococcal disease among the elderly in Australia would be similar to the costs for the prevention of one hospitalisation or death due to influenza. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2192 / 2198
页数:7
相关论文
共 26 条
[1]   Cost-effectiveness of pneumococcal vaccination of older people:: A study in 5 western European countries [J].
Ament, A ;
Baltussen, R ;
Duru, G ;
Rigaud-Bully, C ;
de Graeve, D ;
Örtqvist, Å ;
Jönsson, B ;
Verhaegen, J ;
Gaillat, J ;
Christie, P ;
Cifre, AS ;
Vivas, D ;
Loiseau, C ;
Fedson, DS .
CLINICAL INFECTIOUS DISEASES, 2000, 31 (02) :444-450
[2]   Impact numbers in health policy decisions [J].
Attia, J ;
Page, J ;
Heller, RF ;
Dobson, AJ .
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2002, 56 (08) :600-605
[3]  
*AUSTR I HLTH WELF, 2002, 2002 INFL VACC SURV
[4]  
Australian Government Actuaries, 1999, AUSTR LIF TABL 1995
[5]   PNEUMOCOCCAL POLYSACCHARIDE VACCINE EFFICACY - AN EVALUATION OF CURRENT RECOMMENDATIONS [J].
BUTLER, JC ;
BREIMAN, RF ;
CAMPBELL, JF ;
LIPMAN, HB ;
BROOME, CV ;
FACKLAM, RR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (15) :1826-1831
[6]   The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known [J].
Fedson, DS ;
Anthony, J ;
Scott, G .
VACCINE, 1999, 17 :S11-S18
[7]   Population estimates of persons presenting to general practitioners with influenza-like illness, 1987-96: a study of the demography of influenza-like illness in sentinel practice networks in England and Wales, and in The Netherlands [J].
Fleming, DM ;
Zambon, M ;
Bartelds, AIM .
EPIDEMIOLOGY AND INFECTION, 2000, 124 (02) :245-253
[8]  
Gold MR, 1996, COST EFFECTIVENESS H
[9]   THE EFFICACY OF INFLUENZA VACCINATION IN ELDERLY INDIVIDUALS - A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL [J].
GOVAERT, TME ;
THIJS, CTMCN ;
MASUREL, N ;
SPRENGER, MJW ;
DINANT, GJ ;
KNOTTNERUS, JA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (21) :1661-1665
[10]   Annual incidence rate of infectious diseases estimated from sentinel surveillance data in Japan [J].
Hashimoto, S ;
Murakami, Y ;
Taniguchi, K ;
Shindo, N ;
Osaka, K ;
Fuchigami, H ;
Nagai, M .
JOURNAL OF EPIDEMIOLOGY, 2003, 13 (03) :136-141